Streetbeat News

Products Services

AAPL

Apple Inc. (NASDAQ:AAPL) is expected to launch the iPhone 15 with major upgrades, including a light bezel, USB-C port, and camera improvements. The new model will feature a 'truly all-screen' design with no borders around the display and no cutouts for camera or sensors. The iPhone 15 Pro model will have a new design partly made of stronger, lighter, and more premium titanium. The pricing is expected to increase across all four models outside of the U.S.

Portfolio Pulse from Shanthi Rexaline

July 30, 2023 | 4:34 pm

REGN

Regeneron Pharmaceuticals announced positive two-year results from the pivotal PHOTON trial investigating aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema. The results were presented at the American Society of Retina Specialists annual meeting. 89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining their vision and anatomic improvements.

Portfolio Pulse from Charles Gross

July 30, 2023 | 1:43 pm

FDMT

4D Molecular Therapeutics (NASDAQ:FDMT) announced additional positive interim clinical data from the Phase 1 Dose Exploration stage of the 4D-150 Phase 1/2 PRISM clinical trial for patients with wet age-related macular degeneration (wet AMD). The data showed a dose response in favor of the highest tested dose, with a 100% reduction in supplemental anti-VEGF injections and a clinically meaningful reduction in mean central subfield thickness at 36 weeks. The treatment remained well tolerated at all doses in all patients. Phase 2 Dose Expansion initial interim efficacy and safety data presentation is expected in H1 2024.

Portfolio Pulse from Charles Gross

July 30, 2023 | 1:40 pm

APLS

Apellis Pharmaceuticals provided an update on its review of rare events of retinal vasculitis reported in real-world treatment with SYFOVRE for geographic atrophy. The company confirmed seven total events since launch, with more than 68,000 SYFOVRE vials distributed to date. There was no indication that drug product or manufacturing issues contributed to these events.

Portfolio Pulse from Charles Gross

July 30, 2023 | 1:38 pm

AAPL

Apple Inc. has admitted to a bug in its Screen Time parental controls, according to a report by the Wall Street Journal. The company has not provided a timeline for when the issue will be resolved.

Portfolio Pulse from Charles Gross

July 30, 2023 | 1:35 pm

AAPL

This week's highlights in the Appleverse include a discount on the Apple MagSafe Battery Pack, a shift in smartphone preferences among young South Koreans towards iPhones, Netflix's decision against developing a native app for Apple's Vision Pro, a lower decline in iPhone shipments compared to the overall smartphone market, and a potential high price tag for the upcoming iPhone 15 Pro Max.

Portfolio Pulse from Benzinga Neuro

July 30, 2023 | 1:00 pm

BLK

TSLA

This week's cryptocurrency news includes the potential impact of a Bitcoin ETF from BlackRock, Elon Musk's support for Dogecoin, Robert Kennedy Jr.'s Bitcoin investment, Congressman Brad Sherman's criticism of Bitcoin, and Tesla's removal of Bitcoin from its payment options. Fundstrat predicts a Bitcoin ETF could boost Bitcoin's price to $180,000. Musk's display of the Dogecoin symbol on Twitter led to an 8% price surge. Kennedy Jr. revealed a $400,000 investment in Bitcoin. Tesla removed Bitcoin from its payment page due to regulatory and environmental concerns.

Portfolio Pulse from Benzinga Neuro

July 30, 2023 | 12:01 am

MRNA

COVID-19 cases are expected to surge again in the U.S., according to data from the Centers for Disease Control And Prevention. This could potentially impact the bottom lines of biopharma companies like Moderna, Inc. (NASDAQ:MRNA), which is expected to report a loss of $4.03 per share in its second-quarter report. However, with experts predicting that COVID-19 will be a recurring theme, these companies may continue to see some revenue from the ongoing pandemic.

Portfolio Pulse from Shanthi Rexaline

July 29, 2023 | 8:33 pm

CTXR

Citius Pharmaceuticals (NASDAQ:CTXR) has received a Complete Response Letter from the FDA regarding its Biologics License Application for LYMPHIR, a treatment for patients with relapsed or refractory cutaneous T-cell lymphoma. The FDA has asked Citius to incorporate enhanced product testing and additional controls. No concerns were raised about the safety and efficacy of the clinical data package submitted with the application.

Portfolio Pulse from Charles Gross

July 29, 2023 | 8:32 pm

TSLA

A recent Bloomberg survey of over 5,600 Tesla Model 3 owners revealed that while the Model 3 received strong scores for performance, ease of use, design, and reliability, owners are becoming less fond of CEO Elon Musk. The survey found that 96% of owners with positive views of Musk would buy a Tesla again, while 91% of those with unfavorable opinions would not. The survey also revealed that Musk's tweets and his acquisition of Twitter have influenced the opinions of Model 3 owners.

Portfolio Pulse from Chris Katje

July 29, 2023 | 5:04 pm